CBD for Cancer

Which potential mechanisms of action of CBD are relevant for inhibiting tumor growth?

CBD primarily affects tumor cells through the following approaches that can inhibit tumor growth:

• Increase of reactive oxygen species (ROS): This imbalance often leads to DNA damage and apoptosis. The increased formation of these "free radicals" damages the genetic material and other vital structures in tumor cells. As a result of such damage, affected cells often initiate a self-destruction program (apoptosis).
• Induction of ER stress: Misfolded proteins trigger the unfolded protein response (UPR), which under certain conditions leads to cell death. The endoplasmic reticulum (ER) is responsible for proper protein folding. If too many faulty proteins accumulate there, a stress response (UPR) occurs, which—if excessive—leads to cell death. CBD can enhance this overload in tumor cells.
• Immunomodulation: CBD can alter the tumor environment so that tumor cells are more easily attacked by immune cells (e.g., via ICAM-1). CBD can affect the tissue around the tumor ("tumor microenvironment") so that defense cells (e.g., certain lymphocytes) act more effectively against cancer cells. One example is the upregulation of the molecule ICAM-1, which makes tumor cells more "visible" to attacking cells.
• Influence on signaling pathways: By binding to receptors (CB1, CB2, TRPV1/2, PPARγ), growth-promoting pathways (e.g., AKT/mTOR, MAPK) are inhibited. Cancer cells often "overdrive" their signaling mechanisms to multiply quickly. CBD can bind to specific receptors (e.g., CB1/CB2, TRPV1/2, PPARγ) and thus reduce the overactive metabolic pathways like AKT/mTOR or MAPK. This slows down growth.
• Inhibition of migration and invasion: Among other things, metastasis is inhibited by the upregulation of TIMP-1 and the blockade of proteolytic enzymes. Tumor cells use enzymes and mechanisms that break down surrounding tissue to spread to other parts of the body. CBD increases TIMP-1, an inhibitor of such enzymes. This makes the migration and invasion of cells more difficult and inhibits metastasis formation.

 How does CBD's effect differ from other cannabinoids like THC in the context of cancer therapy?

Compared to THC, which primarily acts through the CB1 receptor and can cause psychotropic effects, CBD exerts its anticancer effects without causing an intoxication-like state. THC focuses more on CB1/CB2 and is limited in higher doses by its psychoactive component. In contrast, CBD has a comparatively low affinity for CB1/CB2 and can influence various tumor cell mechanisms (e.g., ROS formation, ER stress) without causing the same side effects. Thus, CBD is generally better tolerated in cancer therapy and causes fewer central nervous system effects than THC.

CBD differs from THC mainly in how it interacts with the receptors of the endocannabinoid system and the resulting effects:

Psychoactivity

• THC binds with high affinity to the CB1 receptor, which can lead to psychotropic effects (intoxication). This psychoactive component limits its therapeutic benefit at higher doses.
• CBD on the other hand, has only a low affinity for CB1/CB2 and does not cause intoxication. This often makes higher dosing better tolerated.

Mechanistic diversity

• CBD acts on multiple target structures (e.g., TRPV1/2, PPARγ) and thereby influences central tumor cell processes such as increased cellular stress (ROS, ER stress) or migratory ability (e.g., through TIMP-1 upregulation).
• THC acts mainly through the classical cannabinoid receptors CB1 and CB2. Although THC also shows anticancer activity, its therapeutic use is more limited by dose restrictions due to its psychotropic effects.

Therapeutic implications

• CBD is often described as better tolerated because it has fewer central nervous system side effects. It can also support the effect of conventional therapies (e.g., chemotherapeutics) without patients experiencing the typical intoxication effects. 
• THC can also promote anti-tumor processes at lower doses, such as inhibiting tumor growth. However, the simultaneous psychoactive effect requires more precise dose adjustment.

CBD is considered a non-intoxicating component of the cannabis plant that triggers multiple mechanisms against tumor cells while minimizing the side effects that can occur with THCcan occur with preparations containing higher doses.

What study results are currently available that indicate a direct anticancer effect of CBD?

Evidence status

Preclinical evidence (cell culture and animal models)

• Wide range of tumor types (glioblastoma, breast, lung, prostate cancer, colon carcinoma, leukemias) were studied. In all cases, it was found in vitro a significant inhibition of cell proliferation, induction of apoptosis, and partial reduction of metastasis (e.g., through upregulation of ICAM-1, TIMP-1).
• Synergies with Chemotherapeutics: Particularly emphasized are the positive combination effects of CBD with Gemcitabine (pancreatic cancer), Doxorubicin (including breast and liver cancer cells), Cisplatin (e.g., head/neck tumors, lung cancer), Oxaliplatin (colon cancer), and Temozolomide (glioblastoma). In animal models, such CBD+chemo combinations often improved therapy response and reduced resistance.
• Mechanisms: The antitumor effects are mainly explained by increased ROS generation, endoplasmic reticulum stress, inhibition of growth-promoting signaling pathways (AKT/mTOR, MAPK), and immunomodulation (e.g., better recognition of tumor cells by immune cells).

Small clinical studies and case reports

• glioblastoma: A pilot study (CBD/THC spray in addition to Temozolomide) showed possible survival benefits, although final publications are still pending. Individual case observations also suggest that high-grade brain tumors may progress more slowly or remain stable under CBD treatment.
• pancreatic and breast cancer: Experience reports and animal studies suggest sensitization to standard therapies, but larger clinical investigations are lacking here.
• lung carcinoma: One case report describes tumor regression with exclusive use of CBD oil. Whether this is causally related to CBD can only be assessed to a limited extent; nevertheless, it shows that initial clinical indications exist.

Overall assessment

The majority of results come from in vitro- or in vivo-studies with solid methodology but still limited transferability to humans.
Clinical data—apart from a few small studies and case series—are not yet extensive enough to make a definitive recommendation for CBD as a sole cancer therapy. However, the existing evidence is promising: They support the idea that CBD not only has tumor-inhibiting properties but can often achieve higher efficacy or lower resistance in combination with classical therapies (chemotherapy, radiation). All the studies discussed here provide clear preclinical evidence for the direct anticancer activity of CBD. Initial small studies and case reports also suggest it could have positive effects in humans. However, broad clinical application still requires large-scale, controlled studies to clearly determine dosage, efficacy, and long-term safety.

To what extent can CBD as a supportive measure increase or complement the effectiveness of conventional cancer therapies (e.g., chemotherapy, radiation)?

Improved response rate and reduced resistance development

• glioblastoma: In in vitro- and in vivo-In models (e.g., U87MG, T98G), CBD combined with Temozolomide (TMZ) significantly enhanced growth inhibition compared to TMZ alone. An initial pilot study on oromucosal CBD/THC spray + TMZ suggests extended survival times.
• Pancreatic carcinoma: In mice, gemcitabine combined with CBD showed significantly better results (longer survival); CBD appears to reduce resistance and increase cancer cell sensitivity.
• Colorectal cancer: CBD can enhance oxaliplatin and 5-FU (FOLFOX), among other things by increasing oxidative stress and blocking resistance mechanisms.

Reduction of side effects

• Pain and neuropathies: Some studies show that CBD can alleviate therapy-induced nerve damage (e.g., from paclitaxel) without diminishing the antitumor effect of the cytostatic drug.
• Nausea and vomiting: Similar to THC, CBD can reduce chemo-induced nausea, but without psychoactive side effects.

Possible organ and neuroprotection

• Heart & kidneys: Animal models suggest that CBD can protect against doxorubicin-induced cardiotoxicity or cisplatin-related kidney damage.
• Nervous system: CBD can exert neuroprotective properties, which could mitigate some side effects of chemo- and radiation therapies (e.g., cognitive impairments).

Mechanisms of synergy

• Increase of oxidative stress: By increasing ROS, CBD makes tumor cells more susceptible to DNA damage; chemotherapeutics or radiation then target already "pre-stressed" cells.
• Blockade of growth-promoting signaling pathways: CBD inhibits, among others, AKT/mTOR, NF-κB, and MAPK, which gives conventional therapies more "punch."
• Promotion of immune response: A changed tumor microenvironment can enhance the effectiveness of certain therapies (e.g., radiation therapy) because CBD upregulates ICAM-1 and keeps immune cells active.

Limitations and open questions

• Immunotherapies: Data are partly contradictory. Some observations indicate possible interactions that could affect the efficacy of checkpoint inhibitors. Clear recommendations are missing.
• Dosage and interactions: Standardized protocols on how much CBD in which formulation to administer together with which chemotherapy are still lacking.
• Lack of large clinical studies: Although there are promising initial pilot projects and case series, robust RCTs are needed for widespread use.

Overall, numerous preclinical findings and initial clinical indications suggest that CBD can support conventional cancer therapies and alleviate their side effects. The specific benefits (e.g., extended survival time, reduced resistance) are most clearly demonstrated in glioblastoma, pancreatic, and colon cancer models. However, a definitive assessment in larger, controlled studies is still pending.

What advantages and risks does the combined use of CBD and conventional cancer drugs carry regarding efficacy and side effects?

Advantages

Better efficacy (synergistic effects)

• Inhibition of resistance: In models for pancreatic cancer (CBD + gemcitabine) and colon cancer (CBD + oxaliplatin), CBD was able to reduce resistance and increase chemotherapy effectiveness.
• Enhanced tumor cell damage: CBD partly increases oxidative stress (ROS), making tumor cells more vulnerable—conventional cytostatics then encounter already weakened cells.
• Improved tolerability: Studies suggest that CBD can reduce neuro- and organ-toxic effects of some cytostatics (e.g., paclitaxel, cisplatin, doxorubicin) without worsening therapy success.

Reduced side effects

• Relief of nausea and vomiting: CBD can combat chemo-induced nausea, similar to THC, but without strong psychotropic effects.
• Pain relief: In chemo- or tumor pain-related neuralgia, CBD-containing preparations can provide additional analgesic effects.

Risks

Possible interactions

• Cytochrome P450 inhibition: CBD can inhibit certain enzymes (e.g., CYP2C9, CYP2D6) involved in the breakdown of cancer drugs; this could unexpectedly alter their plasma levels.
• Unclear effects on immunotherapies: Some indications suggest a possible weakening of the immune response (e.g., with checkpoint inhibitors); however, solid studies are lacking.

• Dosage uncertainty
  

  • Lack of standardized protocols: Neither the optimal amount of CBD (pure form or full spectrum) nor the timing relative to chemo-/radiotherapy is reliably established. Too much CBD could, for example, enhance interactions, while too little shows no effect.
    

• Insufficient clinical data
  

  • Large RCTs needed: Although many benefits have been documented preclinically, comprehensive controlled studies on combination therapy are still lacking. This complicates clear therapy recommendations.

The combination of CBD and conventional oncological drugs primarily offers the potential for better efficacy and fewer side effects but carries the risk of pharmacokinetic interactions and still unresolved interactions. The existing study results are promising, but a definitive assessment requires further large-scale clinical trials.

 How does CBD affect the immune system and tumor-associated inflammation, which play an important role in cancer development and progression?

Activities

Change of the tumor environment

• CBD can increase the expression of certain molecules like ICAM-1. This cell adhesion molecule facilitates the recognition and destruction of tumor cells by the body's defense cells (e.g., lymphokine-activated killer cells).

Activation or sensitization of immune cells

• Some findings suggest that CBD supports the function of immune effector cells (such as T cells, macrophages) by modifying proinflammatory or immunosuppressive factors in the tumor environment. This strengthens the body's natural cancer defense.

Reduction of harmful inflammatory mechanisms

• Tumor cells use certain inflammatory processes to grow and suppress immune reactions. CBD can act here— for example, by blocking or weakening signaling pathways like NF-κB—thus dampening these processes so the immune system can attack the tumor more effectively.

Inhibition of immune resistance strategies

• In some cancers, an increase in regulatory T cells or myeloid-derived suppressor cells (MDSC) is observed, which block the immune response to the tumor. According to preclinical data, CBD could reduce this effect by modulating signaling pathways that attract or activate these immunosuppressive cells.

Synergies and open questions

• Initial evidence shows that CBD, combined with radiotherapy or chemotherapy, can further support the local immune system and thus enhance the antitumor effect.
• At the same time, there is uncertainty about how CBD interacts with newer immunotherapies (e.g., checkpoint inhibitors), as it can also downregulate inflammatory processes. Currently, there is a lack of reliable clinical data in this area.

CBD can activate the immune system against tumor cells and influence tumor-associated inflammation so that the tumor is less able to "escape" immune detection. This immunomodulatory effect may complement conventional oncological therapies but remains the subject of intensive research.

Which dosage and administration forms of CBD prove particularly effective or safe in current studies?

From the studies and case reports discussed here, it appears that so far no uniformly recommended standard dosage for CBD. Nevertheless, some trends and practical approaches can be identified:

Dosage range

• Studies on glioblastoma and breast cancer: Doses between 100 and 400 mg/day (oral) were observed in some patients, leading to clinically relevant effects. Case reports documented oral doses up to 600 mg/day, though with significant individual variation. Pilot studies with oromucosal sprays (e.g., CBD/THC 1:1) indicate that even relatively low CBD amounts (a few mg per spray over the day) can have an effect, especially in combination with other cannabinoids.

Forms of administration

• Oils/tinctures (Sublingual/Oral): Widely used and most frequently documented in case reports. Patients dose in milliliter increments, with the exact CBD content varying from product to product.
• Capsules/tablets: Allow for more consistent dosing but are less commonly found in studies and are not uniformly standardized.
• Oromucosal sprays: Used especially in combination with THC (e.g., in glioblastoma pilot studies). Advantage: relatively consistent drug absorption and better dose control.
• Full-spectrum vs. isolate products: Preclinical studies especially suggest that full-spectrum CBD (“entourage effect”) may have somewhat better efficacy than pure isolate. However, clinical evidence is largely lacking.

Tolerance and safety

• Generally well tolerated: Most patients show only mild side effects (e.g., fatigue, dry mouth, occasional nausea).
• Interactions: High doses can inhibit cytochrome P450 enzymes, which alters plasma levels of other medications. This is especially important to consider in patients undergoing chemotherapy.

Although case series and smaller studies suggest a a wide range from 50 mg up to several hundred milligrams There is no fixed regimen for all cancer types, as daily references vary. The choice of dosage and form of administration is usually an individual decision, depending on tolerance, product availability, and accompanying therapies. Larger, standardized studies are needed to clearly define optimal amounts and methods of administration.

How can CANNEFF CBD suppositories alleviate side effects of cancer therapy?

In many cancer treatments – especially chemotherapy and radiation – not only tumor cells but also healthy cells, such as those of the mucous membranes, are attacked. Since these mucous membrane cells have a high division rate, they are particularly susceptible to the toxic effects of the treatment. Damage to the mucous membranes leads to inflammation, pain, dryness, and impaired wound healing, which can be observed, for example, in oral or vaginal mucositis symptoms. These side effects can significantly affect the well-being of patients and represent an important aspect of therapy that supportive measures like CANNEFF VAG SUP are specifically designed to address.

CANNEFF VAG SUP Vaginal suppositories combine 100 mg cannabidiol (CBD) and sodium hyaluronate in a patented emulsion matrix. This innovative formulation ensures rapid and complete delivery of both active ingredients, optimizing local absorption and minimizing systemic effects. CANNEFF unfolds its antioxidant and anti-inflammatory properties, contributing to the neutralization of reactive oxygen species (ROS) and stabilization of the redox balance. At the same time, hyaluronic acid supports the moisture supply of the vaginal mucosa, promotes tissue regeneration, and alleviates symptoms such as vaginal dryness, pain during intercourse, vaginal inflammations, and complaints that may occur during chemotherapy and hormonal treatment. The targeted local application via suppositories leads to a rapid effect (within about 60 minutes) and thus enables effective relief of therapy-related side effects, making CANNEFF VAG SUP a promising component of an integrative oncological care concept.

Sources

Seltzer, E. S., Watters, A. K., MacKenzie, D., Jr, Granat, L. M., & Zhang, D. (2020). Cannabidiol (CBD) as a Promising Anti-Cancer Drug. Cancers, 12(11), 3203. https://doi.org/10.3390/cancers12113203

O'Brien K. (2022). Cannabidiol (CBD) in Cancer Management. Cancers, 14(4), 885. https://doi.org/10.3390/cancers14040885

Heider, C. G., Itenberg, S. A., Rao, J., Ma, H., & Wu, X. (2022). Mechanisms of Cannabidiol (CBD) in Cancer Treatment: A Review. Biology, 11(6), 817. https://doi.org/10.3390/biology11060817

Nahler G. Phytocannabinoids as Chemotherapy Adjuncts—A Review for Users. Onco. 2024; 4(4):287-321. https://doi.org/10.3390/onco4040021

Nahler G. (2022). Cannabidiol and Other Phytocannabinoids as Cancer Therapeutics. Pharmaceutical medicine, 36(2), 99–129. https://doi.org/10.1007/s40290-022-00420-4

Nahler G, Jones TM (2018) Pure Cannabidiol versus Cannabidiol-Containing Extracts: Distinctly Different Multi-Target Modulators. J Altern Complement Integr Med 4: 048. 10.24966/ACIM-7562/100048